The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Olumiant. It is the first ever in the United States for a hair loss drug that acts on the whole body. The condition, which often manifests as patchy baldness, affects more than 300,000 people in the United States each year, the FDA said in its statement.
The now-approved tablets have been tested for more than six months in two studies involving patients who have lost at least 50 percent of their hair, the FDA wrote. The measure of the drug’s effectiveness was the number of patients who had regained at least 80% hair coverage in the 36th week.
On the NYSE, Eli Lilly stock temporarily fell 1.06% to $ 288.19.
/ aae / DP / nas
SILVER SPRING (dpa-AFX)
The leverage must be between 2 and 20
No data
Other news about Eli Lilly and Co.
Image sources: Katherine Welles / Shutterstock.com, Jonathan Weiss / Shutterstock.com
